(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2010 (24.06.2010)

PCT

(10) International Publication Number
WO 2010/071232 A1

(51) International Patent Classification:
A61K 31/7034 (2006.01) *A61K 47/36* (2006.01)
A61K 9/20 (2006.01) *A61K 47/38* (2006.01)
A61K 47/10 (2006.01) *A61K 47/42* (2006.01)
A61K 47/32 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/JP2009/071522

(22) International Filing Date:
17 December 2009 (17.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2008-321257 17 December 2008 (17.12.2008) JP

(71) Applicants *(for all designated States except US)*: **SATO PHARMACEUTICAL CO., LTD.** [JP/JP]; 5-27, Motoakasaka 1-chome, Minato-ku, Tokyo, 1070051 (JP). **Bayer Yakuhin, Ltd.** [JP/JP]; 4-9, Umeda 2-chome, Kita-ku, Osaka-shi, Osaka, 5300001 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MATSUI, Kiyotaka** [JP/JP]; c/o SATO PHARMACEUTICAL CO., LTD., 8-5, Higashioi 6-chome, Shinagawa-ku, Tokyo, 1400011 (JP). **HAYASHI, Kunihiro** [JP/JP]; c/o SATO PHARMACEUTICAL CO., LTD., 8-5, Higashioi 6-chome, Shinagawa-ku, Tokyo, 1400011 (JP). **TATARA, Mitsutoshi** [JP/JP]; c/o SATO PHARMACEUTICAL CO., LTD., 8-5, Higashioi 6-chome, Shinagawa-ku, Tokyo, 1400011 (JP). **YAMANOUCHI, Yuka** [JP/JP]; c/o Bayer Yakuhin, Ltd., 4-9, Umeda 2-chome, Kita-ku, Osaka-shi, Osaka, 5300001 (JP).

(74) Agents: **TSUJII, Koichi** et al.; NAKAMURA & PARTNERS, Shin-Tokyo Bldg., 3-1, Marunouchi 3-chome, Chiyoda-ku, Tokyo, 1008355 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/071232 A1

(54) **Title**: A DISINTEGRATING TABLET

(57) **Abstract**: The present invention provides a disintegrating tablet which displays excellent disintegrating ability, strength and drug stability while containing a hygroscopic drug. Specifically, the present invention provides a disintegrating tablet comprising a drug having an equilibrium moisture content of 10-20% under a relative humidity of 75% at 25°C, erythritol, mannitol, and hydroxypropyl cellulose having an equilibrium moisture content of 5-20% under a relative humidity of 75% at 25°C and having a viscosity of 100-2000 cps when being in the form of an aqueous solution of 20% by mass at 37°C, wherein said disintegrating tablet contains said drug in an amount of 15-50% by mass of the total amount of said disintegrating tablet and has porosity of 10-40%.